NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery systems, today announced that Diabetes,
Obesity, and Metabolism, has published an original article
titled "Efficacy and safety of 28-day treatment with
oral insulin (ORMD-0801) in patients with type 2 diabetes mellitus
- A randomized placebo-controlled trial" authored by Dr.
Roy Eldor, Dr. Joel Neutel, Kenneth
Homer and Oramed's Chief Scientific Officer,
Dr. Miriam Kidron.
The article presents the results of a trial that assessed the
safety and efficacy of Oramed's lead drug candidate
ORMD-0801 in type 2 diabetes (T2DM). The trial met its primary
endpoint and found that in patients with T2DM, bedtime ORMD-0801
curbed increases in night-time glycemia, 24-hour glycemia, and
HbA1c without increasing the risk of hypoglycemia or safety events
as compared to the control arm.
"I'm proud and excited that this paper, exploring the
interesting and important results of Oramed's Phase 2 study of oral
insulin has been published by Diabetes, Obesity and
Metabolism," said Roy Eldor,
M.D. Ph.D., Director, Diabetes Unit, Institute of Endocrinology,
Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center,
and a member of Oramed's Scientific Advisory Board.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform
technology pioneer in the field of oral delivery solutions for
drugs currently delivered via injection. Established in 2006, with
offices in the United States and Israel, Oramed has
developed a novel Protein Oral Delivery (PODâ„¢) technology. Oramed
is seeking to transform the treatment of diabetes through its
proprietary lead candidate, ORMD-0801, which is being
evaluated in two pivotal Phase 3 studies and has the potential to
be the first commercial oral insulin capsule for the
treatment of diabetes. In addition, Oramed is developing an oral
GLP-1 (Glucagon-like peptide-1) analog capsule.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the potential efficacy
and safety of ORMD-0801, the ability of Oramed to transform the
treatment of diabetes and the potential of ORMD-0801 to be the
first commercial oral insulin capsule for the treatment of
diabetes. In addition, historic results of scientific research and
clinical trials do not guarantee that the conclusions of future
research or trials will suggest identical or even similar
conclusions. These forward-looking statements are based on the
current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties
related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Logo -
https://mma.prnewswire.com/media/647544/Oramed_Pharmaceuticals_Logo.jpg
Company Contact
Josh
Hexter
+1-844-9-ORAMED
josh@oramed.com
View original
content:https://www.prnewswire.com/news-releases/oramed-announces-publication-of-oral-insulin-study-in-peer-reviewed-journal-diabetes-obesity-and-metabolism-301355754.html
SOURCE Oramed Pharmaceuticals Inc.